Mizuho raised the firm’s price target on ResMed (RMD) to $290 from $270 and keeps an Outperform rating on the shares. The firm sees no evidence of weight loss drug shares losses for ResMed in its quarterly report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target raised to $270 from $240 at Stifel
- ResMed price target raised to $270 from $248 at Piper Sandler
- ResMed price target raised to $305 from $283 at Baird
- ResMed price target raised to $325 from $285 at UBS
- Resmed’s Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating